Trial Profile

Phase 2 Study to Assess the Efficacy and Safety of SPY002-072 in Adults With Moderately to Severely Active Rheumatologic Disease

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SPY 072 (Primary)
Indications Axial spondyloarthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis
Focus Proof of concept; Therapeutic Use
Acronyms SKYWAY-RD
Sponsors Spyre Therapeutics

Most Recent Events

15 Sep 2025 According to Spyre Therapeutics media release, the company announced that topline 12-week (RA) and 16-week (PsA, axSpA) proof-of-concept data are expected in 2026.
15 Sep 2025 According to Spyre Therapeutics media release, the company announced that the first patient has been dosed.
10 Sep 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com